» Articles » PMID: 19491608

Second Neoplasms After Invasive and Borderline Ovarian Cancer

Overview
Specialty Oncology
Date 2009 Jun 4
PMID 19491608
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Excess risk of subsequent cancers has been documented in women diagnosed with ovarian cancer. We updated to 2006 data on second cancers in women diagnosed with invasive and borderline ovarian cancer in the Swiss canton of Vaud. Between 1974 and 2006, 304 borderline and 1530 invasive first ovarian tumours were abstracted from the Vaud Cancer Registry database and followed up till the end of 2006. Calculation of expected numbers of tumours in the cohorts was based on site-specific, age-specific and calendar-year-specific incidence rates. We computed the standardized incidence ratios (SIRs) of second cancers, and the corresponding 95% confidence intervals (CI). There was no change in the incidence of malignant cancers, but that of borderline tumours increased over more recent years. Overall, 110 second neoplasms were observed versus 49.7 expected after invasive ovarian cancer (SIR 2.21; 95% CI: 1.82-2.67). Significant excess risks were observed for cancers of the breast, corpus uteri and leukaemias. When synchronous cancers were excluded, the overall SIR for all sites declined to 1.05. Thirty-one second neoplasms were observed after borderline tumours compared with 21.1 expected (SIR=1.47; 95% CI: 1.00-2.09). SIRs were above unity for ovary, colorectum and uterus. After exclusion of synchronous neoplasms, SIR for all neoplasms declined to 1.09, and remained significant only for second ovarian cancers (SIR=4.93). The present record linkage cohort study shows an excess risk for selected synchronous neoplasms in women diagnosed with both borderline and invasive ovarian cancer, likely because of shared genetic and perhaps environmental factors.

Citing Articles

Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.

Dobilas A, Jansaker F, Li X, Sundquist K, Borgfeldt C BMC Cancer. 2023; 23(1):951.

PMID: 37807065 PMC: 10561436. DOI: 10.1186/s12885-023-11453-6.


Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study.

Lee E, Lim J, Ha H, Lim M, Chang Y, Won Y Front Oncol. 2023; 13:1208320.

PMID: 37781206 PMC: 10539581. DOI: 10.3389/fonc.2023.1208320.


Risk of nonovarian cancer in a nationwide-based study of nearly 5000 women with borderline ovarian tumors in Denmark.

Hannibal C, Baandrup L, Hertzum-Larsen R, Vang R, Kurman R, Frederiksen K Int J Cancer. 2022; 152(7):1370-1377.

PMID: 36366853 PMC: 10099848. DOI: 10.1002/ijc.34354.


The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus.

Chen M, Lee K, Lu C, Wang T, Huang S, Chen C Cancer Med. 2018; 7(6):2299-2306.

PMID: 29659167 PMC: 6010879. DOI: 10.1002/cam4.1473.


Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study.

Hung Y, Liu C, Hu Y, Chen M, Li C, Yeh C Medicine (Baltimore). 2015; 94(38):e1626.

PMID: 26402833 PMC: 4635773. DOI: 10.1097/MD.0000000000001626.